相关论文: Predicting Neoadjuvant Chemotherapy Response in Tr…
Neoadjuvant chemotherapy (NAC) is a standard-of-care treatment for locally advanced triple negative breast cancer (TNBC) before surgery. The early assessment of TNBC response to NAC would enable an oncologist to adapt the therapeutic plan…
Neoadjuvant chemotherapy (NAC) response prediction for triple negative breast cancer (TNBC) patients is a challenging task clinically as it requires understanding complex histology interactions within the tumor microenvironment (TME).…
Aim: This study investigates treatment response prediction to neoadjuvant chemotherapy (NACT) in breast cancer patients, using longitudinal contrast-enhanced magnetic resonance images (CE-MRI) and clinical data. The goal is to develop…
Objectives: To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Materials \& Methods: Patients with BC treated by NAC with a breast…
Effective therapy decisions require models that predict the individual response to treatment. This is challenging since the progression of disease and response to treatment vary substantially across patients. Here, we propose to learn a…
Pathological complete response (pCR) is a key prognostic factor in breast cancer patients undergoing neoadjuvant therapy, strongly associated with long-term survival and treatment personalization. However, accurate pre-treatment pCR…
Objective Neoadjuvant chemotherapy (NACT) is one kind of treatment for advanced stage ovarian cancer patients. However, due to the nature of tumor heterogeneity, the clinical outcomes to NACT vary significantly among different subgroups.…
We proposed a novel convolutional restricted Boltzmann machine CRBM-based radiomic method for predicting pathologic complete response (pCR) to neoadjuvant chemotherapy treatment (NACT) in breast cancer. The method consists of extracting…
Objectives: High-grade serous ovarian carcinoma (HGSOC) is typically diagnosed at an advanced stage with extensive peritoneal metastases, making treatment challenging. Neoadjuvant chemotherapy (NACT) is often used to reduce tumor burden…
Rationale and Objectives: Early prediction of pathological complete response (pCR) can facilitate personalized treatment for breast cancer patients. To improve prediction accuracy at the early time point of neoadjuvant chemotherapy, we…
Predicting response to neoadjuvant therapy is a vexing challenge in breast cancer. In this study, we evaluate the ability of deep learning to predict response to HER2-targeted neo-adjuvant chemotherapy (NAC) from pre-treatment dynamic…
Ovarian cancer is the most lethal gynecologic malignancy: around 60% of patients are diagnosed at an advanced stage, with an associated 5-year survival rate of about 30%. Early identification of non-responders to neoadjuvant chemotherapy…
Triple-negative breast cancer (TNBC) is an aggressive disease with high mortality and limited treatment options, due to its lack of receptors that have targeted therapies available. The tumor microenvironment (TME) plays a critical role in…
Effective surgical planning for breast cancer hinges on accurately predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Diffusion-weighted MRI (DWI) and machine learning offer a non-invasive approach for early…
Neoadjuvant chemotherapy (NAC) is a common therapy option before the main surgery for breast cancer. Response to NAC is monitored using follow-up dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Accurate prediction of NAC…
Monitoring Neoadjuvant chemotherapy (NAC) effects is necessary to capture resistant patients and stop or change treatment. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on…
Purpose. High-grade serous ovarian carcinoma (HGSOC) is characterized by pronounced biological and spatial heterogeneity and is frequently diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by delayed primary surgery…
Early prediction of pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) for breast cancer plays a critical role in surgical planning and optimizing treatment strategies. Recently, machine and deep-learning based…
For many patients, current ovarian cancer treatments offer limited clinical benefit. For some therapies, it is not possible to predict patients' responses, potentially exposing them to the adverse effects of treatment without any…
In breast cancer, neoadjuvant chemotherapy (NAC) provides a standard treatment option for patients who have locally advanced cancer and some large operable tumors. A patient will have better prognosis when he has achieved a pathological…